Benharroch Daniel, Pilosof Shai, Gopas Jacob, Levi Itai
1. Departments of Pathology, Soroka University Medical Center, Israel;
J Cancer. 2012;3:322-7. doi: 10.7150/jca.4716. Epub 2012 Jul 24.
We recognized a few possible complications of classical Hodgkin lymphoma therapy in a cohort of 209 patients: 8 developed a primary refractory disease (primary progression), 36 showed an early relapse and 21 showed a late relapse. Sialyl-CD15 expression in Hodgkin-Reed-Sternberg cells was significantly more positive in primary refractory Hodgkin lymphoma, which confirms our previously published findings. Bcl-2 showed a significantly lower level of expression in primary refractory disease than in the other follow-up groups. This is in contrast with a previous finding of Bcl-2, associated with a poor prognosis in primary refractory illness. Another category of variables, old age and advanced stages, was significantly different in the various complications but this finding is probably to be expected. We could not demonstrate a difference between the sequels and the control group with regard to several clinical and immunohistochemical markers. Sialyl-CD15 and Bcl-2 expression, in contrast, were confirmed as prognostic factors, mainly of tumor progression into primary refractory disease.
我们在一个209名患者的队列中识别出经典型霍奇金淋巴瘤治疗的一些可能并发症：8例出现原发性难治性疾病（原发性进展），36例早期复发，21例晚期复发。霍奇金-里德-斯腾伯格细胞中的唾液酸化CD15表达在原发性难治性霍奇金淋巴瘤中显著更阳性，这证实了我们之前发表的研究结果。Bcl-2在原发性难治性疾病中的表达水平显著低于其他随访组。这与之前关于Bcl-2与原发性难治性疾病预后不良相关的研究结果相反。另一类变量，即老年和晚期，在各种并发症中存在显著差异，但这一发现可能在意料之中。关于几个临床和免疫组化标志物，我们未能证明后遗症组与对照组之间存在差异。相比之下，唾液酸化CD15和Bcl-2表达被确认为预后因素，主要是肿瘤进展为原发性难治性疾病的预后因素。
